EyeGene (Korea) Top Management
185490 Stock | KRW 2,875 5.00 0.18% |
EyeGene employs about 63 people. The company is managed by 10 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 6.3 employees per reported executive. Analysis of EyeGene's management performance can provide insight into the company performance.
Won Yoo CEO President, Chief Executive Officer, Director |
EyeGene |
EyeGene Management Team Effectiveness
The company has return on total asset (ROA) of (0.19) % which means that it has lost $0.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (51.1998) %, meaning that it generated substantial loss on money invested by shareholders. EyeGene's management efficiency ratios could be used to measure how well EyeGene manages its routine affairs as well as how well it operates its assets and liabilities.EyeGene Workforce Comparison
EyeGene is rated second in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 1,024. EyeGene holds roughly 63.0 in number of employees claiming about 6% of stocks in Biotechnology industry.
EyeGene Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. EyeGene Price Series Summation is a cross summation of EyeGene price series and its benchmark/peer.
EyeGene Notable Stakeholders
An EyeGene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as EyeGene often face trade-offs trying to please all of them. EyeGene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting EyeGene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Won Yoo | President, Chief Executive Officer, Director | Profile | |
Du Kim | Director | Profile | |
Wan Cho | Director | Profile | |
Song Kim | Assistant Managing Director | Profile | |
Jin Jang | Assistant Managing Director | Profile | |
Myeong Lee | Assistant Managing Director | Profile | |
WonIl Yoo | Chief Pres | Profile | |
YangJe Cho | CoFounder Officer | Profile | |
Soobeom Lee | Chief Officer | Profile | |
Jong Choi | Internal Auditor | Profile |
About EyeGene Management Performance
The success or failure of an entity such as EyeGene often depends on how effective the management is. EyeGene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of EyeGene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the EyeGene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea. Eyegene is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of EyeGene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, EyeGene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of EyeGene's management manipulating its earnings.
EyeGene Workforce Analysis
Traditionally, organizations such as EyeGene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare EyeGene within its industry.EyeGene Manpower Efficiency
Return on EyeGene Manpower
Revenue Per Employee | 51.5M | |
Revenue Per Executive | 324.2M | |
Net Loss Per Employee | 548.7M | |
Net Loss Per Executive | 3.5B |
Complementary Tools for EyeGene Stock analysis
When running EyeGene's price analysis, check to measure EyeGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EyeGene is operating at the current time. Most of EyeGene's value examination focuses on studying past and present price action to predict the probability of EyeGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EyeGene's price. Additionally, you may evaluate how the addition of EyeGene to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |